SCHEMBL6547677

SCHEMBL6547677

CC(=NOCC(C)C)c1ccc(COc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HTT P42858 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
GCGR P47871 4/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
ADCYAP1R1 P41586 1/20 0.31
GLRA1 P23415 1/20 0.31
CCR5 P51681 1/20 0.30
PPARG P37231 1/20 0.30
PPARA Q07869 1/20 0.30
NR1H4 Q96RI1 1/20 0.30
RXRA P19793 1/20 0.30
RXRB P28702 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549405 0.91 NPC1 (0.35) SMN1; SMN2NPC1RAB9AHTTHRH3
SCHEMBL6549004 0.90 NPC1 (0.35) SMN1; SMN2NPC1RAB9AHTTHRH3
SCHEMBL6548809 0.88 HTT (0.33) SMN1; SMN2NPC1RAB9AHTTHRH3
SCHEMBL6547273 0.87 NPC1 (0.44) SMN1; SMN2NPC1RAB9AHTTL3MBTL1
SCHEMBL6548169 0.87 GCGR (0.31) GCGRADCYAP1R1
SCHEMBL6548842 0.86 HRH3 (0.43) HTTHRH3GCGRMAPTMAOA
SCHEMBL6549656 0.85 ESR1 (0.36) SMN1; SMN2NPC1RAB9AHTTHRH3
SCHEMBL6548722 0.85 ALDH1A1 (0.35) SMN1; SMN2HTTHRH3GCGRALDH1A1
SCHEMBL6549867 0.84 HTT (0.36) HTTHRH3MAPTMAOAMAOB
SCHEMBL6547607 0.84 HTT (0.33) HTTHRH3GCGRMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 SMN1; SMN2 2474/4885NPC1 1404/4885RAB9A 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.